Management of osteoporosis in older people

Journal of Pharmacy Practice and Research

Volumn 40, Issue 3, 2010, Pages 229-234

  Inderjeeth, Charles A ^a,b   Poland, Kate E ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

AUSTRALIA; BONE FRAGILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENVIRONMENTAL FACTOR; EXERCISE; FALL RISK; FRACTURE; HEREDITY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR; RISK REDUCTION; SENILE OSTEOPOROSIS;

EID: 77957995079     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2010.tb00545.x     Document Type: Review

References (56)

1. Nguyen T V, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180(suppl):S18-S22.
2. Inderjeeth CA, Foo AC, Lai MM, Glendenning P. Efficacy and safety of pharmacological agent in managing osteoporosis in the old old: review of the evidence. Bone 2009;44:744-51.
3. Access Economics. A future less fragile. North Ryde: Novartis Australia Pty Ltd; 2010. Available from .
4. Sambrook PN, Seeman E, Phillips SR, Ebling PR; Osteoporosis Australia, National Prescribing Service. Preventing osteoporosis: outcomes of the Australia Fracture Prevention Summit. Med J Aust 2002;176(suppl):S1-S6.
5. The European Prospective Osteoporosis Study Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study. J Bone Miner Res 2002;17:716-24.
6. Sanders KM, Seeman E, Ugoni AM, Pasco JA, Martin TJ, Skoric B, et al. Ageand gender-specific rate of fractures in Australia: a population based study. Osteoporos Int 1999;10:240-7.
7. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study. Osteoporos Int 1994;4:277-82.
8. Sanders KM, Nicholson GC, Ugoni AM, Pasco JA, Seeman E, Kotowicz MA. Health burden of hip and other fractures in Australia beyond 2000: projections based on the Geelong osteoporosis study. Med J Aust 1999;170:467-70.
9. Gullberg G, Johnell O, Kanis JA. Worldwide projections for hip fracture. Osteoporos Int 1997;7:407-13.
10. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report series 843. Geneva: World Health Organization; 1994.
11. Kanis JA, Glüer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000;11:192-202.
12. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet 2005;366:1885-93.
13. Tinetti M, Speechley M, Ginter S. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7.
14. Centre for Disease Control and Prevention. Fatalities and injuries from falls among older adults - United States, 1993-2003 and 2001-2005. MMWR 2006;55:1221-4.
15. American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guidelines for prevention of falls in older persons. J Am Geriatr Soc 2001;49:664-72.
16. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming R G, Close JC. Effective exercise for the prevention of falls: a systematic review and metaanalysis. J Am Geriatr Soc 2008;56:2234-43.
17. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, et al. Do hip protectors decrease the risk of hip fracture in institutional and communitydwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2005;16:1461-74.
18. Duque G, Close JJ, de Jager J P, Ebeling PR, Inderjeeth CA, Lord S, et al. Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. Med J Aust 2010;193:173-9.
19. Sanders KM, Nowson CA, Kotowicz MA, Briffa K, Devine A, Reid IR. Working Group: Australian and New Zealand Bone and Mineral Society and Osteoporosis Australia. Calcium and bone health: position statement. Med J Aust 2009;190:316-20.
20. Chapuy MC, Arlot ME, Delmas PD, Meunier P. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2.
21. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262-6.
22. Working Group of the Australian and New Zealand Bone and Mineral Society; Endocrine Society of Australia; Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005;182:281-5.
23. Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein M, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003;51:1533-8.
24. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxy vitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
25. Parikh S, Avorn J, Solomon DH. Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc 2009;57:327-34.
26. Hackman KL, Gagnon C, Briscoe RK, Lam S, Anpalahan M, Ebeling PR. Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D. Med J Aust 2010;192:686-9.
27. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women. JAMA 2010;303:1815-22.
28. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older. Lancet 2007;370:657-66.
29. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch Intern Med 1997;157:2617-24.
30. Black DM, Cummings SR, Karpf DB, Cauley J, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
31. Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long term care facilities. Ann Intern Med 2002;136:742-6.
32. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton I, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women age 80 and older: implication for the use of antiresorptive agent in the old and oldest old. J Am Geriatr Soc 2004;52:1832-9.
33. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with post-menopausal osteoporosis. JAMA 1999;282:1344-52.
34. Reginster J, Minne HW, Sorenson OH, Hooper M, Roux C, Brandi ML, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
35. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;334:333-40.
36. Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 2009;4:445-9.
37. McCloskey EV, Beneton M, Charleswoth D, Kayan K, de Takats D, Dey A, et al. Clodronate reduces the incidence of fracture in community dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled study, J Bone Miner Res 2007;22:135-41.
38. Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eiksen EF, et al. Efficacy and safety of a once yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9.
39. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
40. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
41. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, et al. Strontium ranelate reduce the risk of vertebral and non-vertebral fractures in women 80 years of age and older. J Bone Miner Res 2006;21:1113-20.
42. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68. (Pubitemid 38133766)
43. Reginster Y, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of non vertebral fracture in post menopausal women with osteoporosis: treatment of peripheral osteoporosis. J Clin Endocrinol Metab 2005;90:2816-22.
44. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
45. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006;54:2617-24.
46. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J Y, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
47. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45.
48. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
49. Reginster J, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi M, et al. Effects of long-term strontium ranelate treatment in the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum 2008;58:1687-95.
50. Seeman E, Boonen S, Borgstrom F, Vellas B, Aquino J, Semler J, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010;46:1038-42.
51. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patients' adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2010. Doi:10.1007/s00198-010-1335-x.
52. Riggs BL, Warner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with ageing: differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 1982;71:716-23.
53. Sambrook PN, Cameron ID, Chen JS, Cumming RG, Lord SR, March LM, et al. Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 2007;18:603-10.
54. Gardner MJ, Brophy RH, Demetrakopolous D, Koob J, Hong R, Rana A, et al. Interventions to improve osteoporosis treatment following a hip fracture. J Bone Joint Surg Am 2005;87:3-7.
55. Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-7.
56. Borgström F, Johnell O, Kanis JA, Jönsson B, Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006;17:1459-71.